your quality of life is good
Haibo Si, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Action Required : If approved, clients must prepare for these changes starting with January 1, 2026 renewals communication and planning are essential
B12 Shots & B12 Injections: Assessing the Pros, Cons, and Effects that Linger for a Few Days
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)
GLP-1 drugs are not the enemy